


INTRODUCTION

- Imetelstat is a first-in class direct and competitive inhibitor of telomerase that specifically targets malignant clones with abnormally high telomerase activity, enabling recovery of effective hematopoiesis¹⁻⁴
- Unmet need remains for RBC transfusion-dependent patients with LR-MDS R/R to or ineligible for ESAs
- In the phase 2 part of the IMerge study, patients with LR-MDS who were heavily RBC transfusion dependent, R/R to or ineligible for ESAs, non-del(5g), and naive to lenalidomide and HMA achieved durable and continuous RBC-TI when treated with imetelstat, with an 8-week RBC-TI rate of 42% and a median TI duration of 86 weeks⁵
- This poster presents the analysis of phase 3 results from IMerge in the same patient population (Fig. 1)

Figure 1. IMerge Phase 3 Trial Design (MDS3001; NCT02598661)



 $^{\alpha}$ Received \geq 8 weeks of ESA treatment (epoetin alfa \geq 40,000 U, epoetin beta \geq 30,000 U, or darbepoetin alfa 150 μ g or equivalent per week) without Hb rise \geq 1.5 g/dL or decreased RBC transfusion requirement \geq 4 U every 8 weeks or transfusion dependence or reduction in Hb by \geq 1.5 g/dL after hematologic improvement from \geq 8 weeks of ESA treatment. ^bProportion of patients without any RBC transfusion for \geq 8 consecutive weeks since entry to the trial (8-week TI); proportion of patients without any RBC transfusion for \geq 24 consecutive weeks since entry to the trial (24-week TI).

AIM

- To assess rates of 8- and 24-week RBC-TI, duration of RBC-TI, and hematologic improvement with imetelstat vs placebo in phase 3 of the IMerge study in patients overall and stratified by prior RBC-TB and IPSS category
- To assess frequency and magnitude of AEs with imetelstat vs placebo

METHODS

Study Design

- IMerge phase 3 is a double-blind, randomized (2:1), placebo-controlled, phase 3 trial conducted at 118 global sites between 2019 and 2022 Patients with heavily RBC transfusion-dependent, ESA-relapsed/refractory/ineligible non-del(5q) LR-MDS naive to lenalidomide/HMA were randomized to receive imetelstat 7.5 mg/kg (n = 118) or placebo (n = 60) every 4 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or lack of response
- Primary end point was 8-week TI rate; key secondary end points include 24-week RBC-TI, duration of TI, HI-E, and safety
- Primary and secondary end points were compared using a Cochran-Mantel-Haenszel test stratified by prior RBC TB and IPSS category, and TI duration was calculated by Kaplan-Meier method and compared via the stratified log-rank test

ACKNOWLEDGMENTS

- Previously presented as an oral presentation at the European Hematology Association (EHA) 2023 congress The authors thank the patients and caregivers for their participation 3. Mosoyan G, et al. *Leukemia*. 2017;31(11):2458-2467. in this study and acknowledge the collaboration and commitment of 4. Wang X, et al. *Blood Adv.* 2018;2(18):2378-2388.
- the investigators and their research support staff All authors contributed to and approved the presentation
- Writing and editorial assistance was provided by Erin McMullin, PhD, and Mary C. Wiggin of Ashfield MedComms, an Inizio Company

DISCLOSURES

Uwe Platzbecker received honoraria from Geron, AbbVie, BMS, Janssen, Jazz, Silence Therapeutics, and Takeda

CONTACT INFORMATION

IMerge (MDS3001): https://www.geron.com/patients/imerge-study ClinicalTrials.gov: NCT02598661; email mds3001-info@geron.com

REFERENCES

1. Asai A, et al. Cancer Res. 2003;63(14):3931-3939.

- 2. Herbert B-S, et al. Oncogene. 2005:24(33):5262-5268.

ABBREVIATIONS

5. Steensma DP, et al. J Clin Oncol. 2021;39(1):48-56. 6. Platzbecker U, et al. *Blood*.

2019;133(10):1020-1030.



1 10 10

AE, adverse event; ALT, alanine aminotransferase; AML, acute myeloid leukemia; AARM(1,1), autoregressive moving average; BCORL1, BCL6 corepressor like 1; COVID-19, coronavirus disease of 2019; DCO, data cutoff; EPO, erythropoietin; ESA, erythropoiesis-stimulating agent; FACIT, Functional Assessment of Chronic Illness Therapy; G-CSF, granulocytecolony stimulating factor; GNB1, G protein subunit beta 1; Hb, hemoglobin; HI-E, hematologic improvement-erythroid; HMA, hypomethylating agent; HR, hazard ratio; HTB, high transfusion burden; IPSS, International Prognostic Scoring System; IPSS-R, International Prognostic Scoring System-Revised; IPSS-M, International Prognostic Scoring System-Molecular; ITT, intent-to-treat; IV, intravenous; IWG, International Working Group; LR, lower risk; LTB, low transfusion burden; MDS, myelodysplastic neoplasms; NE, not estimable; *MLL*-PTD, mixed lineage leukemia partial tandem duplication *PPM1D*, protein phosphatase; PRO, patient-reported outcome; R, randomization; RBC, red blood cell; R/R, relapsed/refractory; RS, ring sideroblast; sEPO, serum erythropoietin; SETBP1, SET binding protein 1; TEAE, treatmentemergent adverse event; TB, transfusion burden; TI, transfusion independence; WHO, World Health Organization.

CONTINUOUS TRANSFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC NEOPLASMS RELAPSED/REFRACTORY/INELIGIBLE FOR **ERYTHROPOIESIS-STIMULATING AGENTS IN IMErge PHASE III**

U. PLATZBECKER^{1*}, V. SANTINI^{2**}, P. FENAUX³, M.A. SEKERES^{4**}, M.R. SAVONA⁵, Y.F. MADANAT⁶, M. DÍEZ-CAMPELO⁷, D. VALCÁRCEL-FERREIRAS⁸, T. ILLMER⁹, A. JONÁŠOVÁ¹⁰, P. BĚLOHLÁVKOVÁ¹¹, L. SHERMAN¹², S. DOUGHERTY¹², S. SHAH¹², Q. XIA¹², L. PENG¹², L. SUN¹², Y. WAN¹², F. HUANG¹², A. IKIN¹², S. NAVADA¹², F. FELLER¹², R.S. KOMROKJI¹³, A.M. ZEIDAN^{14*}

¹Leipzig University Hospital, Leipzig, Germany; ²Azienda Ospedaliero Universitaria Careggi, University of Florence, Italy; ³Hôpital Saint-Louis, University of Miami, FL, USA; ⁵Vanderbilt University Medical Center, Nashville, TN, USA; ⁶Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA; ⁷University Hospital Oniversitari Vall d'Hebron, Barcelona, Spain; ⁹Hematology Private Practice, Dresden, Germany; ¹⁰General Hospital, Prague, Czech Republic; ¹¹Charles University Hospital, Hradec Kralove, Czech Republic; ¹²Geron Corporation, Parsippany, NJ, USA; ¹³Moffitt Cancer Center, Tampa, FL, USA; ¹⁴Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT, USA. *Contributed equally.

RESULTS

Demographics and Disease Characteristics

- The study comprised 118 and 60 patients in the imetelstat and placebo arms, respectively (Table 1A)
- Imetelstat and placebo arms had similar distributions of patients by demographics, disease characteristics, and IPSS-R and IPSS-M risk categories (Table 1A and B)
- Similar percentages of patients discontinued treatment in the imetelstat and placebo arms (Table 1C)
- Discontinuations due to AEs were reported by 19 of 118 patients (16.1%) treated with imetelstat and 0 of 59 patients (0%) treated with placebo; 11 of 118 patients (9.3%) treated with imetelstat discontinued due to cytopenias
- Discontinuation due to disease progression occurred in 7 of 118 patients (5.9%) treated with imetelstat and 5 of 59 patients (8.5%) treated with placebo

Table 1. Demographics and Disease Characteristics (A), Risk Categorization (B), and **Treatment Exposure and Disposition With 18 Month Median Follow-up (C)**

Α		
Characteristic	Imetelstat (n = 118)	Placebo (n = 60)
Age, median (range), y	72 (44-87)	73 (39-85)
Male, n (%)	71 (60)	40 (67)
Time since diagnosis, median (range), y	3.5 (0.1-26.7)	2.8 (0.2-25.7)
WHO classification, n (%) RS+ RS-	73 (62) 44 (37)	37 (62) 23 (38)
IPSS risk category, n (%) Low Intermediate-1	80 (68) 38 (32)	39 (65) 21 (35)
Pretreatment Hb, median (range), ^a g/dL	7.9 (5.3-10.1)	7.8 (6.1-9.2)
Prior RBC transfusion burden, median (range), RBC U/8 wk	6 (4-33)	6 (4-13)
Prior RBC transfusion burden, n (%) ≥4 to ≤6 U/8 wk >6 U/8 wk	62 (53) 56 (48)	33 (55) 27 (45)
sEPO, median (range), mU/mL	174.9 (6.0-4460.0)	277.0 (16.9-5514.0)
sEPO level, n (%) ^ь ≤500 mU/mL >500 mU/mL	87 (74) 26 (22)	36 (60) 22 (37)
Prior ESA, n (%)	108 (92)	52 (87)
Prior luspatercept, n (%) ^c	7 (6)	4 (7)

DCO date, October 13, 2022. ^aAverage of all Hb values in the 8 weeks before the first dose date, excluding values within 14 days after a ransfusion, which was considered to be influenced by transfusion. ^bData missing for 5 patients in the imetelstat group and 2 in the placebo group. Insufficient number of patients previously treated with luspatercept to draw conclusions about the effect of imetelstat treatment in such patients.

_							
IPSS-R, n (%)ª	Imetelstat (n = 118)	Placebo (n = 60)	Total (N = 178)	IPSS-M, n (%)ª	Imetelstat (n = 103)	Placebo (n = 52)	Total (N = 155)
Very low	3 (2.5)	2 (3.3)	5 (2.8)	Very low	4 (3.9)	0	4 (2.6)
Low	87 (73.7)	46 (76.7)	133 (74.7)	Low	65 (63.1)	33 (63.5)	98 (63.2)
Intermediate	20 (16.9)	8 (13.3)	28 (15.7)	Moderate low	22 (21.4)	10 (19.2)	32 (20.6)
High	1 (0.8)	0	1 (0.6)	Moderate high	7 (6.8)	6 (11.5)	13 (8.4)
Very high	0	0	0	High	4 (3.9)	3 (5.8)	7 (4.5)
Missing	7 (5.9)	4 (6.7)	11 (6.2)	Very high	1 (1.0)	0	1 (0.6)

For IPSS-R, the number included the ITT population. ^bFor IPSS-M, mutation biomarker analysis set included all the patients who received \geq 1 dos of study drug and had baseline mutation data and central cytogenetic data available. Molecular data MLL-PTD, BCORL1, GNB1, PPM1D, and SETBP1 were not assessed in the study.

L		
	Imetelstat (n = 118)	Placebo (n = 59)
Treatment duration, median, wk ^a	33.9	28.3
Treatment ongoing, n (%)	27 (22.9)	14 (23.7)
Treatment discontinued, n (%)	91 (77.1)	45 (76.3)
Lack of efficacy	28 (23.7)	25 (42.4)
Adverse event	19 (16.1)	0
Cytopenias	11 (9.3)	0
Unrelated	8 (6.8)	0
Loss of response ^b	17 (14.4)	1 (1.7)
Disease progression	7 (5.9)	5 (8.5)
Progression to AML	2 (1.7)	1 (1.7)
Death ^c	1 (0.8)	2 (3.4)
Other ^d	19 (16.1)	12 (20.3)


^aMean (SD) duration of treatment was 46.8 (34.3) and 39.6 (29.2) weeks with imetelstat and placebo, respectively. ^bPer IWG 2006 criteria. "Imetelstat group: neutropenic sepsis not related to drug after \sim 2-year treatment duration (n = 1); placebo group: COVID-19 (n = 1) and heart value issue (n = 1). ^dIncluded patient decision (imetelstat group, n = 16; placebo group, n = 10), investigator decision (n = 2 in each group), and lost to follow-up (n = 1 in imetelstat group).


Efficacy

- (Fig. 2A)
- levels (Fig. 3A)


- Table 2A

Responders (B) With Imetelstat vs Placebo





Primary end point 8-week TI and the first secondary end point 24-week TI were statistically significant by the study's prespecified gate-keeping testing procedure. P Value determined by the Cochran-Mantel-Haenszel test, with stratification for prior RBC-TB (\geq 4 to \leq 6 vs >6 RBC U every 8 weeks during a 16-week period prerandomization) and baseline IPSS risk category (low vs intermediate-1) applied to randomization. ^aDCO date, October 13, 2022. ^bDCO date, January 13, 2023.



^{\circ}HR (95% CI) from the Cox proportional hazard model, stratified by prior RBC TB (\geq 4 to \leq 6 vs >6 RBC U per 8 weeks during a 16-week period prerandomization) and baseline IPSS risk category (low vs intermediate-1), with treatment as the only covariate. ^bP Value (2-sided) for superiority of imetelstat vs placebo in HR based on stratified log-rank test.

		Imetelstat median (95% CI), wk	Placebo median (95% CI), wk	Hazard ratio (95% Cl)	P Value
Overall		51.6 (26.9-83.9)	13.3 (8.0-24.9)	0.23 (0.09-0.57)	<.001
WHO category RS+ RS-		46.9 (25.9-83.9) 51.6 (11.9-NE)	16.9 (8.0-24.9) 11.2 (10.1-NE)	0.32 (0.11-0.95) 0.11 (0.01-1.43)	.035 .062
Prior RBC transfusion burden per IWG 2006			100/404 24 0	0.25 (0.12,0.00)	025
4-6 U/8 wk >6 U/8 wk		51.9 (24.9-122.9) 39.9 (15.9-NE)	16.9 (10.1-24.9) 8.4 (8.0-NE)	0.35 (0.13-0.96) 0.04 (0.003-0.48)	.035 <.001
IPSS risk category Low Intermediate-1		43.9 (25.0-NE) 51.6 (11.9-NE)	15.1 (8.0-24.9) 10.1 (NE-NE)	0.26 (0.10-0.68) 0.15 (0.01-2.47)	.004 .128
Baseline sEPO ≤500 mU/mL >500 mU/mL		51.6 (26.9-83.9) 122.9 (8.14-NE)	13.3 (8.0-24.9) 14.6 (12.3-NE)	0.21 (0.075-0.61) 0.34 (0.03-3.85)	.002 .364
Prior ESA use Yes No		43.9 (26.9-80.0) 122.9 (8.14-NE)	13.3 (8.0-24.9) 14.6 (12.3-NE)	0.26 (0.10-0.72) 0.34 (0.03-3.85)	.006 .364
	0.001 0.01 0.1 1 10 100 Hazard ratio Favors imetelstat Favors placebo	•			

and the second s

(A) HR (95% CI) from the Cox proportional hazard model and (B) 95% CI based on Wilson Score method. P Value determined by the Cochran-Mantel-Haenszel test, stratified by prior RBC TB (≥ 4 to ≤ 6 vs > 6 RBC U per 8 weeks during a 16-week period before randomization) and baseline IPSS risk category (low vs intermediate-1), with treatment as the only covariate. P Value (2-sided) for superiority of imetelstat vs placebo in HR based on stratified log-rank test (A).

• Primary end point of 8-week RBC-TI rate was significantly higher with imetelstat vs placebo

• Imetelstat 8-week RBC-TI responders had significantly longer duration of TI vs placebo (Fig. 2B) • Among patients treated with imetelstat, there was a significant and sustained increase in Hb

• Greater reduction in mean RBC transfusion units over time with imetelstat vs placebo (Fig. 3B) • HI-E rates with imetelstat vs placebo are shown in Fig. 3C


• Durability of RBC-TI for 8-week TI responders across key LR-MDS subgroups is shown in


• 24-Week RBC-TI rates were comparable across key LR-MDS subgroups (Table 2B)

Figure 2. RBC-TI Rates at 8 Weeks to 1 Year (A) and Duration of RBC-TI in 8-Week

Table 2. Durability of RBC-TI for 8-Week TI Responders (A) and 24-Week RBC-TI Rate (B) Across Key LR-MDS Subgroups

Figure 3. Improvement in Hb Levels (A), Transfusion Burden (B), and HI-E Response (C) With Imetelstat vs Placebo





^aMean changes from the minimum Hb levels of the values that were after 14 days of transfusions in the 8 weeks before the first dose date are shown (A). Data points that have <4 patients are not shown (B). P Value based on a mixed model for repeated measures with Hb change (A) or change in RBC transfusions (B) as the dependent variable, week, stratification factors, minimum Hb level in the 8 weeks before the first dose date (A) or prior TB (B), treatment group, and treatment and week interaction term as the independent variables with ARMA(1,1) covariance structure.


L			
Hematologic improvement	Imetelstat (n = 118)	Placebo (n = 60)	% Difference <i>P</i> value ^a
HI-E (IWG 2018 ⁶), n (%) 95% Cl ^b	50 (42.4) 33.3-51.8	8 (13.3) 5.9-24.6	29.0 <.001
Patients with LTB, n ^c HI-E response (16-wk RBC-TI), n (%) 95% Cl ^b	21 7 (33.3) 14.6-57.0	18 4 (22.2) 6.4-47.6	11.1 .562
Patients with HTB, n ^c Major HI-E response (16-wk RBC-TI), n (%) 95% Cl ^b Minor HI-E response (50% RBC U reduction in 16 wk), n (%) 95% Cl ^b	97 30 (30.9) 21.9-41.1 43 (44.3) 34.2-54.8	42 0 (0.0-8.4) 4 (9.5) 2.7-22.6	30.9 <.001 34.8 <.001


^aP Value based on Cochran-Mantel-Haenszel controlling for prior RBC TB (≤ 6 vs >6 RBC U) and IPSS risk group (low vs intermediate-1) applied to randomization. ^bExact Clopper-Pearson CI. ^cPer revised IWG 2018, patient with LTB was a patient who received 3 to 7 RBC U in the 16 weeks before study entry in \geq 2 transfusion episodes and a patient with HTB was a patient who received \geq 8 RBC U in the 16 weeks before study entry in ≥ 2 transfusion episodes.


		Imetelstat n/N (%)	Placebo, n/N (%)	% Difference (95% Cl)	P Value
Overall	·	33/118 (28.0)	2/60 (3.3)	24.6 (12.64-34.18)	<.001
WHO category	I				
RS+		24/73 (32.9)	2/37 (5.4)	27.5 (10.00-40.37)	.003
RS-		9/44 (20.5)	0/23 (0.0)	20.5 (-0.03 to 35.75)	.019
Prior RBC transfusion	L. C.				
burden per IWG 2006	1				
4-6 U/8 wk	·	19/62 (30.6)	2/33 (6.1)	24.6 (5.68-38.66)	.006
>6 U/8 wk		14/56 (25.0)	0/27 (0)	25.0 (6.44-38.65)	.012
IPSS risk category					
Low	·	23/80 (28.8)	2/39 (5.1)	23.6 (7.23-35.75)	.003
Intermediate-1		10/38 (26.3)	0/21 (0)	26.3 (3.46-43.39)	.009
Baseline sEPO	1				
≤500 mU/mL	·	29/87 (33.3)	2/36 (5.6)	27.8 (10.46-39.71)	.002
>500 mU/mL		4/26 (15.4)	0/22 (0)	15.4 (-5.81 to 35.73)	.050
Prior ESA use	1				
Yes		31/108 (28.7)	2/52 (3.8)	24.9 (11.61-35.00)	<.001
No		2/10 (20)	0/8	20.0 (-23.47-55.78)	.225
-4	0 -20 0 20 40 60				
	Percent difference				

Favors placebo Favors imetelstat

MDS-572







Safety

- Consistent with prior clinical experience, the most common AEs were hematologic, consisting of grade 3-4 thrombocytopenia and neutropenia most often reported during cycles 1-3 (**Table 3**) No fatal hematologic AEs occurred
- Nonhematologic AEs were generally low grade
- Incidence of grade 3 liver function test laboratory abnormalities was similar in imetelstat vs placebo - No cases of Hy's Law or drug-induced liver injury observed

Table 3. AEs With Imetelstat vs Placebo

$\nabla r_{a} (>10\%)$ of motion $r_{a} (\%)$	Imetelsta	t (n = 118)	Placebo) (n = 59)
AEs (≥10% of patients), n (%)	Any grade Grade 3-4		Any grade	Grade 3-4
lematologic				
Thrombocytopenia	89 (75)	73 (62)	6 (10)	5 (8)
Neutropenia	87 (74)	80 (68)	4 (7)	2 (3)
Anemia	24 (20)	23 (19)	6 (10)	4 (7)
Leukopenia	12 (10)	9 (8)	1 (2)	0
Dther				
Asthenia	22 (19)	0	8 (14)	0
COVID-19	22 (19) ^a	2 (2) ^b	8 (14) ^a	3 (5) ^b
Headache	15 (13)	1 (1)	3 (5)	0
Diarrhea	14 (12)	1 (1)	7 (12)	1 (2)
ALT increased	14 (12)	3 (3)	4 (7)	2 (3)
Edema peripheral	13 (11)	0	8 (14)	0
Hyperbilirubinemia	11 (9)	1 (1)	6 (10)	1 (2)
Pyrexia	9 (8)	2 (2)	7 (12)	0
Constipation	9 (8)	0	7 (12)	0

^aIncluded COVID-19, asymptomatic COVID-19, and COVID-19 pneumonia. ^bOnly COVID-19 pneumonia events were grade 3-4 COVID-19

• Cytopenias were of short duration and were manageable (**Table 4A**)

- Median duration of grade 3-4 thrombocytopenia and neutropenia was <2 weeks
- Greater than 80% of events resolved to grade ≤2 within 4 weeks
- 41 Patients (34.7%) in the imetelstat group and 2 patients (3.4%) in the placebo group had ≥1 dose of a myeloid growth factor mostly within cycles 2-4
- Clinical consequences of grade 3-4 infection and bleeding were low and similar for imetelstat and placebo (Table 4B)

Table 4. Duration (A) and Clinical Consequences (B) of Grade 3-4 Cytopenias

Α			В		
Grade 3-4 cytopenias per lab value	lmetelstat (n = 118)	Placebo (n = 59)	Grade ≥3 AEs, n (%)	Imetelstat (n = 118)	Placebo (n = 59)
Thrombocytopenia			Bleeding events	3 (2.5)	1 (1.7)
Duration, median (range), wk Resolved within 4 wk, %	1.4 (0.1-12.6) 86.3	2.0 (0.3-11.6) 44.4	Infections	13 (11.0)	8 (13.6)
Neutropenia			Febrile neutropenia	1 (0.8)	0
Duration, median (range), wk	1.9 (0-15.9)	2.2 (1.0-4.6)			
Resolved within 4 wk, %	81.0	50.0			

Imetelstat TEAEs were managed with dose modification (Table 5)

- Most AEs leading to dose modifications were grade 3–4 neutropenia and thrombocytopenia
- 74% of patients treated with imetelstat had dose modifications due to AEs but <15% discontinued
- treatment due to TEAEs

– Median time to discontinuation of imetelstat due to a TEAE was 21.1 weeks (range, 2.3 to 44.0 weeks)

Table 5. Frequency of Dose Modification and Treatment Discontinuation for TEAEs

Patients with dose modifications, n (%)	Imetelstat (n = 118)	Placebo (n = 59)
Any dose delay due to TEAEs	81 (68.6)	14 (23.7)
Dose reduction due to TEAE	58 (49.2)	4 (6.8)
Treatment discontinuation due to TEAE	17 (14.4)	0

CONCLUSIONS

- In this heavily transfusion dependent LR-MDS population in need of novel therapy, imetelstat demonstrated statistically significant and clinically meaningful efficacy compared with placebo
- Robust RBC-TI rates: 40% with 8-week RBC-TI and 28% with 24-week RBC-TI (DCO date, October 13, 2022) and 18% with 1-year RBC-TI (DCO date, January 13, 2023)
- Median RBC-TI duration approached 1 year for 8-week RBC-TI responders
- Increased Hb levels and HI-E per IWG 2018
- Rate of 24-week RBC-TI was higher with imetelstat vs placebo across subgroups grouped by RS status, RBC TB, IPSS risk category, or sEPO status
- Safety results were consistent with prior imetelstat clinical experience, with no new safety signals - Severe clinical consequences from grade 3-4 cytopenias were similar in patients treated with imetelstat and placebo
- Encouraging durability was observed with imetelstat treatment in LR-MDS patients who were heavily RBC transfusion dependent and R/R to or inelegible for ESAs